Published in J Endotoxin Res on January 01, 2001
Immunosuppression following surgical and traumatic injury. Surg Today (2010) 1.36
Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun (2006) 1.05
Macrophage migration inhibitory factor in patients with preterm parturition and microbial invasion of the amniotic cavity. J Matern Fetal Neonatal Med (2005) 1.01
A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. Biochemistry (2009) 0.98
A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study. J Transl Med (2009) 0.91
Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages. Infect Immun (2005) 0.88
Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. Proc Natl Acad Sci U S A (2016) 0.84
Macrophage migration inhibitory factor in fetoplacental tissues from preeclamptic pregnancies with or without fetal growth restriction. Clin Dev Immunol (2011) 0.82
Tissue regeneration using macrophage migration inhibitory factor-impregnated gelatin microbeads in cutaneous wounds. Am J Pathol (2005) 0.82
Role of macrophage migration inhibitory factor in age-related lung disease. Am J Physiol Lung Cell Mol Physiol (2015) 0.80
Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis. PLoS Negl Trop Dis (2010) 0.79
A dynamic model of gene expression in monocytes reveals differences in immediate/early response genes between adult and neonatal cells. J Inflamm (Lond) (2007) 0.79
A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76
Altered Macrophage and Dendritic Cell Response in Mif-/- Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 Diabetes. J Diabetes Res (2016) 0.75
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (2000) 3.81
CD14 is a pattern recognition receptor. Immunity (1994) 3.79
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2002) 3.10
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun (1994) 2.92
Natural history of aortic valve endocarditis in rats. Infect Immun (1982) 2.74
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis (1994) 2.61
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis (1983) 2.35
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis (1993) 2.35
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med (2001) 1.95
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 1.88
Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol (1992) 1.82
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis (1989) 1.64
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother (1995) 1.63
Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med (1996) 1.61
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 1.61
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS (1994) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med (1995) 1.55
Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med (1994) 1.53
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis (1991) 1.50
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother (1990) 1.49
Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 1.47
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother (2001) 1.47
Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis (1995) 1.43
An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis (1995) 1.43
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry (1997) 1.40
Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis (1994) 1.40
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol (2010) 1.38
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun (2000) 1.37
Campylobacter fetus subspecies fetus bacteremia. Arch Intern Med (1985) 1.35
Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol (1992) 1.33
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis (1988) 1.32
Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci U S A (1993) 1.31
Septic shock: treatment. Lancet (1991) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol (1993) 1.30
Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1997) 1.28
Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus intermedius. J Infect Dis (1986) 1.26
Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis (1994) 1.26
Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Antimicrob Agents Chemother (1999) 1.25
[Epidemic listeriosis. Report of 25 cases in 15 months at the Vaud University Hospital Center]. Schweiz Med Wochenschr (1985) 1.25
Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med (Berl) (1998) 1.24
Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med (1987) 1.21
Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med (1996) 1.20
Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J Immunol (1993) 1.20
The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest (2000) 1.19
Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest (1978) 1.18
Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. Infect Immun (2001) 1.18
Molecular basis of host-pathogen interaction in septic shock. Curr Opin Microbiol (1998) 1.18
Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother (1986) 1.17
Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob Agents Chemother (1994) 1.16
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother (1998) 1.15
Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity. J Biol Chem (1999) 1.13
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother (1996) 1.12
Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob Agents Chemother (1994) 1.11
Discrepancies between MBC and actual killing of viridans group streptococci by cell-wall-active antibiotics. Antimicrob Agents Chemother (1986) 1.10
Vancomycin prophylaxis of experimental Streptococcus sanguis. Inhibition of bacterial adherence rather than bacterial killing. J Clin Invest (1981) 1.10
Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study. J Infect Dis (1989) 1.10
Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J Infect Dis (1994) 1.10
Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer (1994) 1.10
Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. J Infect Dis (1993) 1.09
Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol (1992) 1.08
Predictors of endocarditis in isolates from cultures of blood following dental extractions in rats with periodontal disease. J Infect Dis (1988) 1.06
Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother (1993) 1.05
Purification and characterization of murine lipopolysaccharide-binding protein. Infect Immun (1993) 1.05
Effect of nitrogen mustard on natural history of right-sided streptococcal endocarditis in rabbits: role for cellular host defenses. Infect Immun (1982) 1.04
Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother (1991) 1.03
Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. J Immunol (2001) 1.03